TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01290601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine + Primaquine
Description: Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafenoquine
Description: Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine + Primaquine
Description: Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
Study: NCT01722149

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Adoptive Transfer of re-directed T cells
Description: Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
Study: NCT00704002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antegrade intramedullary splinting
Description: antegrade intramedullary splinting with 2 to 3 small K-wires

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: conservative treatment with 2-finger splint for one week
Study: NCT01349023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density (ED), Energy content
Description: Standard or reduced energy content and energy density of pre-portioned entrees

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density (ED), Energy content
Description: Standard or reduced energy content and energy density of pre-portioned entrees

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density (ED), Energy content
Description: Standard or reduced energy content and energy density of pre-portioned entrees

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density (ED), Energy content
Description: Standard or reduced energy content and energy density of pre-portioned entrees
Study: NCT02690558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab, gemcitabine and cisplatin
Description: neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
Study: NCT02729103

Intervention type: DRUG
Intervention: Xofigo (Radium 223 dichloride,BAY88-8223)
Description: Retrospective claims analysis. Descriptive analyses of treatment patterns.

Intervention type: DRUG
Intervention: Xofigo (Radium 223 dichloride,BAY88-8223)
Description: Retrospective claims analysis. Descriptive analyses of treatment patterns.
Study: NCT02977117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate magnesium (1.0 mmol/L)
Description: Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate magnesium (0.5 mmol/L)
Description: Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
Study: NCT01765179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate
Description: Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
Study: NCT02608281

Intervention type: DEVICE
Group type: OTHER
Intervention: CONTRAST ENHANCED DUAL ENERGY (CEDEM)
Description: The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
Study: NCT03838107

Intervention type: BEHAVIORAL
Intervention: observation and measure of trajectory of recovery in CRPS
Description: Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.

Intervention type: BEHAVIORAL
Intervention: observation and measure of trajectory of recovery in CRPS
Description: Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.

Intervention type: BEHAVIORAL
Intervention: observation and measure of trajectory of recovery in CRPS
Description: Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
Study: NCT00419783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bilastine
Description: 20 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 100 mg (5 tablets of 20 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine & Ketoconazole
Description: 1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 1 capsule containing moxifloxacin 400 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT01272947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Topical gel 1%- 4 times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical gel - 4 times daily
Study: NCT00279630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthoses and Exercise
Description: orthrose and exercise - daily
Study: NCT04498065

Intervention type: BIOLOGICAL
Intervention: Biological data
Description: Biological data

Intervention type: BIOLOGICAL
Intervention: Biological data
Description: Biological data

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical data

Intervention type: OTHER
Intervention: Clinical data
Description: Clinical data
Study: NCT03037164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTERCEPT Blood System for Red Blood Cells
Description: The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (Control)
Description: Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
Study: NCT01789125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Termination and Anxiety Reduction Treatment
Description: Integrated smoking cessation and anxiety reduction treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education-Supportive Psychotherapy
Study: NCT00287339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg capsule BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule BID for 12 weeks
Study: NCT00564018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Description: Dosage adjusted to meet age-specific glycemic goals throughout course of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH
Description: Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
Study: NCT02670941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender
Description: The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orange
Description: The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jojoba
Description: The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils.
Study: NCT00555490

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 35 % of protein from soy protein for 4-years
Study: NCT02787954

Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure for giving chemotherapy directly to tumor cells.

Intervention type: PROCEDURE
Intervention: Y-90
Description: Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.

Intervention type: PROCEDURE
Intervention: MWA
Description: Using heat to kill tumor cells.

Intervention type: PROCEDURE
Intervention: IRE
Description: Using energy to disrupt tumor cell activity, thereby causing cellular death.
Study: NCT04134676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioned Media
Description: Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
Study: NCT00405470

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advance Medial Pivot Knee Arthroplasty
Description: medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advance Medial Pivot Knee Arthroplasty
Description: medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
Study: NCT01699789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement Program
Description: The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality Improvement Program
Description: The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resources for Services Expert Team
Description: The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning Council
Description: The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
Study: NCT00916825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation programme getting better together
Description: Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
Study: NCT03541382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OraQuick® HIV Self-Test
Description: Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC.
Study: NCT03397849

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention using mobile technology
Description: Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)
Study: NCT02411578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen Mini™ (glucagon injection)
Description: 1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 150 µg of glucagon~2. BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 150 µg of glucagon~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Tablets
Description: 1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates~2. BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)
Study: NCT04233593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: Endotoxin E Coli
Study: NCT02340091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA IDF plus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA IDF
Study: NCT01231516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 50mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1349572 Placebo
Description: Inactive placebo tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir Placebo
Description: Inactive placebo tablet twice daily
Study: NCT03700749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% chlorhexidine + non-coated suture
Description: Interventions:~2% alcoholic chlorhexidine non-coated suture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% chlorhexidine + coated suture
Description: Interventions:~2% alcoholic chlorhexidine triclosan coated suture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10%povidone-iodine + non-coated suture
Description: Interventions:~10% povidone-iodine non-coated suture non-coated suture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10%povidone-iodine + coated suture
Description: Interventions:~10% povidone-iodine triclosan coated suture
Study: NCT01289171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic acid
Description: Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
Study: NCT01677351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 4 mcg.kg-1, 20 minutes before cataract surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01236651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotaverine
Description: administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
Study: NCT03328533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
Study: NCT02460666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-Chi-Chih (TCC)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education and Wellness Classes (HEW)
Study: NCT02479334

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fat challenge breakfast
Description: In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat challenge breakfast+spices
Description: In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate challenge breakfast
Description: In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate challenge breakfast+spices
Description: In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20